Iopodic acid

Iopodic Acid Overview

Iopodic acid (commonly known as ipodate or iopidate) is a tri-iodinated organic compound belonging to the phenylpropanoic acids class under the phenylpropanoids and polyketides superclass. Structurally, it consists of a benzene ring substituted with three iodine atoms at positions 2, 4, and 6, conjugated to an aliphatic propanoic acid chain and an amidine moiety. It has been formulated as sodium and calcium salt derivatives, including ipodate sodium and ipodate calcium.

In clinical radiology, endocrinology, and pharmacology, Iopodic acid served historically as an oral hepatotropic radiopaque contrast agent for cholecystography to visualize the gallbladder and biliary ductal architecture during abdominal X-ray imaging. Additionally, because of its unique biochemical capacity to rapidly block peripheral thyroid hormone conversion, Iopodic acid was utilized off-label in clinical endocrinology for the acute management of severe hyperthyroidism, thyrotoxicosis, and Graves’ disease.

What Is Iopodic Acid and How Does It Work?

Iopodic acid is a small molecule organic iodine derivative that acts both as a physical radiopaque X-ray attenuation medium and as an enzyme antagonist of thyroxine 5′-deiodinase.

Its dual physiological and biochemical mechanisms include:

• Radiopaque X-Ray Attenuation (Cholecystography): Following oral ingestion, the lipid-soluble Iopodic acid is rapidly absorbed from the gastrointestinal tract, bound to serum albumin, and selectively cleared by hepatocytes into bile. The three iodine atoms at positions 2, 4, and 6 on the aromatic ring absorb ionizing X-ray radiation. As concentrated bile collects in the gallbladder, the organ becomes radiopaque, allowing clear visualization of gallbladder morphology, motility, and gallstones on abdominal X-ray film.
• Inhibition of Peripheral T4 to T3 Conversion: In hyperthyroidism, Iopodic acid functions as a potent competitive inhibitor of type I and type II iodothyronine 5′-deiodinase enzymes. By blocking 5′-monodeiodination, it halts the extrathyroidal conversion of inactive thyroxine (T4​) into the active hormone triiodothyronine (T3​), rapidly dropping serum T3​ concentrations within 24 to 48 hours.
• Inhibition of Thyroid Hormone Secretion: Release of inorganic free iodide from the molecule transiently suppresses thyroid hormone synthesis and release via the Wolff-Chaikoff effect.

Is Iopodic Acid FDA Approved?

Yes, Iopodic Acid was approved by the US FDA. It received its official New Drug Application (NDA 013233) approval on March 15, 1962, under the trade name Oragrafin Sodium (and later Oragrafin Calcium) as an oral radiopaque contrast agent for cholecystography and biliary imaging. However, with the clinical rise of non-invasive abdominal ultrasonography and modern antithyroid treatment regimens, commercial production was voluntarily phased out, and the product was officially withdrawn from the US market on August 31, 1989.

What Was Iopodic Acid Used For?

• Epicutaneous oral cholecystography as a diagnostic X-ray contrast agent to visualize the gallbladder and extrahepatic biliary ducts.
• Historical acute management of severe hyperthyroidism, thyroid storm, and Graves’ disease to achieve rapid lowering of circulating serum T3​ levels.
• Preoperative stabilization of hyperthyroid patients undergoing urgent thyroidectomy.

Before Taking Iopodic Acid: Contraindications & Precautions

Do not use if you have a documented severe hypersensitivity or past anaphylactic reaction to iodine, ipodate, or iodinated X-ray contrast media. Strictly contraindicated in severe renal impairment, severe hepatic failure, active jaundice caused by complete biliary obstruction, or severe overt hypothyroidism. Iopodic acid was voluntarily withdrawn from the U.S. market in 1989 due to the rise of non-invasive ultrasonography and modern antithyroid agents. Iodinated contrast agents cross the placenta and pass into breast milk, carrying risks of fetal radiation exposure and thyroid suppression; use during pregnancy is contraindicated unless managing acute, life-threatening hyperthyroidism.

Who Should Not Take Iopodic Acid?

• Individuals with a documented severe hypersensitivity or past anaphylactic reaction to iodine, ipodate, or iodinated X-ray contrast media.
• Patients with severe renal impairment or acute kidney injury, as combined renal and hepatic elimination pathways are compromised.
• Patients with severe hepatic failure or active jaundice caused by complete biliary obstruction (which prevents gallbladder visualization).
• Individuals with severe overt hypothyroidism or those scheduled for diagnostic radioactive iodine (I131) uptake studies in the near future.

Iopodic Acid, Pregnancy & Fertility

Systemic drug exposure occurs readily after oral administration. Radiopaque agents cross the human placenta. Exposure to iodinated contrast media during pregnancy carries risks of fetal radiation exposure and fetal thyroid suppression (congenital hypothyroidism). Iopodic acid is contraindicated during pregnancy unless life-threatening hyperthyroidism requires acute intervention. Inorganic iodide is excreted into human breast milk; nursing should be temporarily suspended if administered.

Tell Your Doctor Before Taking Iopodic Acid

Inform your physician or radiologist if you have a history of bronchial asthma, severe food or drug allergies, renal insufficiency, heart failure, or underlying thyroid disease (such as Graves’ disease or toxic multinodular goiter).

Iopodic Acid Dosage & Administration

Iopodic acid (Oragrafin) is a discontinued, withdrawn medication, rendering clinical dosing guidelines obsolete. Formulated for oral administration in capsule form as sodium or calcium salts. Historically, the adult diagnostic dose for oral cholecystography was 3 grams (six 500 mg capsules) taken with water 10 to 12 hours prior to scheduled X-ray imaging following a fat-free evening meal. For off-label acute hyperthyroidism management, historical dosing ranged from 500 mg to 1000 mg orally once daily for 7 to 14 days. It is no longer manufactured or available for legal medical administration.

Standard Iopodic Acid Dosing

• Oral Cholecystography (Historical Diagnostic Dose): Standard adult dosing was 3 grams (six 500 mg capsules of Oragrafin Sodium) taken orally in the evening following a fat-free meal, approximately 10 to 12 hours prior to scheduled abdominal X-ray imaging.
• Acute Hyperthyroidism / Thyroid Storm (Historical Off-Label Dose): 500 mg to 1000 mg (1 to 2 capsules) orally once daily for 7 to 14 days, often combined with thionamides (methimazole or propylthiouracil) and beta-blockers.

How Iopodic Acid Was Administered

• Administered via the oral route with a full glass of water.
• For cholecystography, patients maintained a strict fat-free diet on the evening of ingestion and remained nil per os (NPO) until imaging was completed.

Iopodic Acid Clinical Efficacy & Research

Clinical literature from the 1960s through 1990s confirmed that Iopodic acid provided high diagnostic accuracy for detecting cholelithiasis and chronic cholecystitis prior to ultrasound technology. In endocrinology trials, Iopodic acid demonstrated rapid clinical efficacy in severe Graves’ disease, decreasing serum T3​ concentrations by up to 60-70% within 48 hours a faster onset than standard thionamides alone. However, prolonged use beyond 14 to 21 days often led to an “escape” phenomenon, where thyroid hormone synthesis resumed as iodine uptake escape occurred.

Iopodic Acid Side Effects & Safety Profile

Common historical reactions included gastrointestinal distress (nausea, vomiting, abdominal cramps, diarrhea), dysuria, urinary frequency, transient headache, and facial flushing. Serious adverse risks included contrast-induced acute kidney injury (AKI), severe anaphylaxis (bronchospasm, laryngeal edema, cardiovascular collapse), iodine-induced hyperthyroidism (Jod-Basedow phenomenon), and transient severe hypothyroidism. Holds no modern FDA Black Box Warning due to its 1989 withdrawal.

Common Iopodic Acid Side Effects

• Mild gastrointestinal irritation, including nausea, vomiting, abdominal cramps, and diarrhea.
• Dysuria, urinary frequency, or mild renal pelvis irritation secondary to urinary iodide clearance.
• Transient headache, dizziness, and mild facial flushing.

Serious Iopodic Acid Adverse Events

• Contrast-Induced Acute Kidney Injury (AKI): Renal tubular damage or acute renal failure, particularly in dehydrated patients or those with pre-existing diabetic nephropathy.
• Severe Hypersensitivity / Anaphylaxis: Urticaria, angioedema, bronchospasm, laryngeal edema, and cardiovascular collapse.
• Thyroid Dysfunction: Iodine-induced hyperthyroidism (Jod-Basedow phenomenon) in patients with autonomous thyroid nodules, or severe transient hypothyroidism.

Managing Iopodic Acid Side Effects

Ensure adequate oral or intravenous hydration before and after administering iodinated contrast media to mitigate contrast-induced nephrotoxicity. Manage severe allergic reactions immediately with epinephrine, antihistamines, and intravenous corticosteroids.

Iopodic Acid Drug Interactions & What to Avoid

Inorganic iodide release competitively blocks thyroid uptake of diagnostic or therapeutic radioactive iodine for 6 to 12 weeks post-administration. Co-administration with nephrotoxic agents (e.g., NSAIDs, aminoglycosides) significantly increases the risk of contrast-induced renal failure. Fat-containing foods must be avoided on the evening of cholecystography ingestion to prevent premature gallbladder contraction prior to imaging.

Iopodic Acid Drug-Drug Interactions

• Radioactive Iodine (I131 / I123): High inorganic iodide levels from Iopodic acid competitively inhibit thyroid uptake of diagnostic or therapeutic radioactive iodine for up to 6 to 12 weeks post-administration.
• Nephrotoxic Agents (e.g., NSAIDs, Aminoglycosides): Concomitant use increases the risk of contrast-induced acute renal dysfunction.

Iopodic Acid, Food & Alcohol

For diagnostic cholecystography, fat-containing foods must be avoided on the evening of drug ingestion to prevent premature gallbladder contraction prior to X-ray imaging.

Iopodic Acid: Missed Dose, Overdose & Storage

Dosing schedules are obsolete due to market withdrawal. Acute overdose causes severe gastrointestinal mucosal irritation, profound diarrhea, dehydration, acute renal failure, and iodism (metallic taste, oral burning, severe skin eruptions), requiring immediate emergency intravenous hydration and supportive care. Legacy or chemical reference samples should be stored in tightly closed containers at room temperature (15°C–30°C) protected from light and excessive moisture.

Missed Dose of Iopodic Acid

Because diagnostic cholecystography relied on strict time-dependent dosing 10 to 12 hours prior to X-ray imaging, a missed dose required rescheduling the diagnostic radiological procedure.

Iopodic Acid Overdose & Emergency

Acute overdose causes severe gastrointestinal irritation, profound diarrhea, dehydration, acute renal failure, and iodine toxicity (iodism), characterized by burning in the mouth, metallic taste, and severe skin eruptions. Seek immediate emergency medical care for fluid rehydration and supportive management.

How to Store Iopodic Acid

Legacy or chemical reference samples should be stored in tightly closed containers at controlled room temperature between 15°C and 30°C (59°F to 86°F), protected from light and excessive moisture. Keep strictly out of reach of children.

Iopodic Acid Patient Management & Monitoring

Historical monitoring required baseline renal function panels (serum creatinine, eGFR, BUN) and baseline thyroid function tests (free T4 , free T3, TSH) prior to administration. Monitor renal output, hydration status, and clinical signs of hypersensitivity during use. In historical hyperthyroid protocols, serial serum T3 and T4 levels were monitored every 48 to 72 hours to evaluate response and assess for thyroid hormone escape.

Tests Before Starting Iopodic Acid

• Baseline renal function panel (serum creatinine, blood urea nitrogen, eGFR).
• Baseline thyroid function panel (free T4​, free T3​, TSH) if evaluating hyperthyroidism.
• Pregnancy screening in women of childbearing potential.

Monitoring During Iopodic Acid Treatment

Monitor renal output, hydration status, and clinical signs of hypersensitivity. In hyperthyroid management, perform serial serum T3​ and T4​ level testing every 48 to 72 hours.

Iopodic Acid Do’s and Don’ts

• Do maintain adequate fluid intake when taking iodinated contrast agents.
• Do inform your radiologist if you have an allergy to iodine or seafood.
• Do not undergo radioactive iodine scans immediately after receiving Iopodic acid.
• Do not reuse discontinued contrast media formulations.

Frequently Asked Questions

References

• DrugBank Database – Iopodic Acid Clinical and Pharmacological Profile (DB09333)
• Classyfire Database – Phenylpropanoic Acids Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.